{
  "first_published_at": "2014-06-20", 
  "original_url": "http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON428305", 
  "title": "Ivabradine: emerging clinical trial evidence of increased cardiovascular riskâ€”carefully monitor for bradycardia", 
  "tags": "{\"parsed_therapeutic\": [\"cardiovascular-disease-lipidology\"], \"Audience:\": [\"Primary care\", \"Secondary care\"], \"Therapeutic area:\": [\"Cardiovascular disease and lipidology\"]}", 
  "_document_number": 22, 
  "label": "Reminder", 
  "icon": "http://www.mhra.gov.uk/home/images/MHRALook/img/dsu/adverse_icon.png", 
  "therapeutic_area": [
    "cardiovascular-disease-lipidology"
  ], 
  "raw_html": "<div id=\"dsuArticleContent\">\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<h1><a name=\"maincontent\" id=\"maincontent\"></a>Ivabradine: emerging clinical trial evidence of increased cardiovascular risk&#8212;carefully monitor for bradycardia</h1>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<span class=\"ref\">Article date: June 2014</span> \r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t<!--Preliminary results have shown a small increase in the combined risk of cardiovascular death and non-fatal myocardial infarction with ivabradine compared with placebo in a subgroup of the SIGNIFY trial.-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t<!--<p>Ivabradine (Procorolan) is used to treat symptoms of long-term stable angina in adults with coronary heart disease who have a normal heart rhythm. Ivabradine is also used in patients with long-term heart failure who have a normal heart rhythm but whose heart rate is at least 75 beats per minute (bpm).</p>\n\n<p>The SIGNIFY trial investigated the efficacy of ivabradine compared with placebo in people with coronary artery disease. The ivabradine dose regimen used in the trial (7.5 to 10 mg twice daily) was higher than the licensed posology (5 to 7.5 mg twice daily). The trial included a pre-specified subgroup analysis of participants with symptomatic angina of CCS class II or more. Preliminary results have shown a small but statistically significant increase in the combined risk of cardiovascular death and non-fatal myocardial infarction with ivabradine compared with placebo in this subgroup. This cardiovascular risk might be associated with a target heart rate below 60 bpm.</p>\n\n<p>The European Medicines Agency is reviewing how the data from the SIGNIFY study impact the balance of benefits and risks of ivabradine. While the review is ongoing, we remind you of the following:</p>\n\n<div class=\"dull_highlight\">\n<p><strong>Advice for healthcare professionals:</strong></p>\n\n<p><em>Posology and monitoring</em></p>\n\n<ul>\n<li>The starting dose of ivabradine is 5 mg twice daily. The maintenance dose should not exceed 7.5 mg twice daily.</li>\n\n<li>Carefully monitor patients for bradycardia or its symptoms (eg, dizziness, fatigue, hypotension).</li>\n\n<li>Down-titrate the dose if resting heart rate decreases persistently below 50 bpm or if the patient experiences symptoms of bradycardia. The dose can be down-titrated to 2.5 mg twice daily if necessary.</li>\n\n<li>Stop ivabradine treatment if the resting heart rate remains below 50 bpm or symptoms of bradycardia persist.</li>\n\n<li>Only increase the dose to 7.5 mg twice daily after 3 to 4 weeks of treatment and if the 5 mg dose is well tolerated but insufficient. Carefully monitor the effect of a dose increase on heart rate.</li>\n</ul>\n\n<p><em>Other considerations</em></p>\n\n<ul>\n<li>Avoid concomitant use of ivabradine with heart rate-reducing calcium channel blockers such as verapamil or diltiazem.</li>\n\n<li>Review the treatment of patients currently using ivabradine where appropriate.</li>\n</ul>\n</div>\n\n<p><strong>Further information</strong></p>\n\n<p><a target=\"_blank\" href=\"http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2014/05/WC500166318.pdf\">European Medicines Agency statement 8 May 2014</a></p>\n\n<p><a href=\"/Opendocuments/OpenPDFdocuments/CON428306\">Letter sent to healthcare professionals in June 2014</a></p>\n\n<p><em>Article citation: Drug Safety Update volume 7 issue 11, June 2014: S1.</em></p>-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t\t\t\t\t\t\t\r\n\r\n<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n\t\t\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t<p>Ivabradine (Procorolan) is used to treat symptoms of long-term stable angina in adults with coronary heart disease who have a normal heart rhythm. Ivabradine is also used in patients with long-term heart failure who have a normal heart rhythm but whose heart rate is at least 75 beats per minute (bpm).</p>\n\n<p>The SIGNIFY trial investigated the efficacy of ivabradine compared with placebo in people with coronary artery disease. The ivabradine dose regimen used in the trial (7.5 to 10 mg twice daily) was higher than the licensed posology (5 to 7.5 mg twice daily). The trial included a pre-specified subgroup analysis of participants with symptomatic angina of CCS class II or more. Preliminary results have shown a small but statistically significant increase in the combined risk of cardiovascular death and non-fatal myocardial infarction with ivabradine compared with placebo in this subgroup. This cardiovascular risk might be associated with a target heart rate below 60 bpm.</p>\n\n<p>The European Medicines Agency is reviewing how the data from the SIGNIFY study impact the balance of benefits and risks of ivabradine. While the review is ongoing, we remind you of the following:</p>\n\n<div class=\"dull_highlight\">\n<p><strong>Advice for healthcare professionals:</strong></p>\n\n<p><em>Posology and monitoring</em></p>\n\n<ul>\n<li>The starting dose of ivabradine is 5 mg twice daily. The maintenance dose should not exceed 7.5 mg twice daily.</li>\n\n<li>Carefully monitor patients for bradycardia or its symptoms (eg, dizziness, fatigue, hypotension).</li>\n\n<li>Down-titrate the dose if resting heart rate decreases persistently below 50 bpm or if the patient experiences symptoms of bradycardia. The dose can be down-titrated to 2.5 mg twice daily if necessary.</li>\n\n<li>Stop ivabradine treatment if the resting heart rate remains below 50 bpm or symptoms of bradycardia persist.</li>\n\n<li>Only increase the dose to 7.5 mg twice daily after 3 to 4 weeks of treatment and if the 5 mg dose is well tolerated but insufficient. Carefully monitor the effect of a dose increase on heart rate.</li>\n</ul>\n\n<p><em>Other considerations</em></p>\n\n<ul>\n<li>Avoid concomitant use of ivabradine with heart rate-reducing calcium channel blockers such as verapamil or diltiazem.</li>\n\n<li>Review the treatment of patients currently using ivabradine where appropriate.</li>\n</ul>\n</div>\n\n<p><strong>Further information</strong></p>\n\n<p><a target=\"_blank\" href=\"http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2014/05/WC500166318.pdf\">European Medicines Agency statement 8 May 2014</a></p>\n\n<p><a href=\"http://www.mhra.gov.uk/home/groups/dsu/documents/publication/con428306.pdf\" target='new\"\"'>Letter sent to healthcare professionals in June 2014<img src=\"http://www.mhra.gov.uk/home/images/MHRALook/img/icon/acroread.gif\" alt=\"PDF file (opens in new window)\" width=\"16\" height=\"16\" title=\"PDF file (opens in new window)\" border=\"0\"></a> (111Kb)</p>\n\n<p><em>Article citation: Drug Safety Update volume 7 issue 11, June 2014: S1.</em></p>\r\n\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_END_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t", 
  "date_of_article": "2014-06-01", 
  "date_last_modified": "2014-06-25", 
  "_assets": [
    {
      "content_type": "application/pdf", 
      "title": "Letter sent to healthcare professionals in June 2014", 
      "assetid": 0, 
      "original_url": "http://www.mhra.gov.uk/home/groups/dsu/documents/publication/con428306.pdf", 
      "filename": "downloads/f9c23907f2121516f85ee8b666d1b018da93e914/con428306.pdf", 
      "original_filename": "con428306.pdf"
    }
  ], 
  "_item_id": 22, 
  "summary": "", 
  "body": "Article date: June 2014\n\nIvabradine (Procorolan) is used to treat symptoms of long-term stable angina in adults with coronary heart disease who have a normal heart rhythm. Ivabradine is also used in patients with long-term heart failure who have a normal heart rhythm but whose heart rate is at least 75 beats per minute (bpm).\n\nThe SIGNIFY trial investigated the efficacy of ivabradine compared with placebo in people with coronary artery disease. The ivabradine dose regimen used in the trial (7.5 to 10 mg twice daily) was higher than the licensed posology (5 to 7.5 mg twice daily). The trial included a pre-specified subgroup analysis of participants with symptomatic angina of CCS class II or more. Preliminary results have shown a small but statistically significant increase in the combined risk of cardiovascular death and non-fatal myocardial infarction with ivabradine compared with placebo in this subgroup. This cardiovascular risk might be associated with a target heart rate below 60 bpm.\n\nThe European Medicines Agency is reviewing how the data from the SIGNIFY study impact the balance of benefits and risks of ivabradine. While the review is ongoing, we remind you of the following:\n\nAdvice for healthcare professionals:\n\nPosology and monitoring  \n  \n  * The starting dose of ivabradine is 5 mg twice daily. The maintenance dose should not exceed 7.5 mg twice daily.  \n  * Carefully monitor patients for bradycardia or its symptoms (eg, dizziness, fatigue, hypotension).  \n  * Down-titrate the dose if resting heart rate decreases persistently below 50 bpm or if the patient experiences symptoms of bradycardia. The dose can be down-titrated to 2.5 mg twice daily if necessary.  \n  * Stop ivabradine treatment if the resting heart rate remains below 50 bpm or symptoms of bradycardia persist.  \n  * Only increase the dose to 7.5 mg twice daily after 3 to 4 weeks of treatment and if the 5 mg dose is well tolerated but insufficient. Carefully monitor the effect of a dose increase on heart rate.  \n  \nOther considerations  \n  \n  * Avoid concomitant use of ivabradine with heart rate-reducing calcium channel blockers such as verapamil or diltiazem.  \n  * Review the treatment of patients currently using ivabradine where appropriate.  \n  \nFurther information\n\n[European Medicines Agency statement 8 May 2014](http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2014/05/WC500166318.pdf)\n\n[ASSET_TAG](#ASSET0) (111Kb)\n\nArticle citation: Drug Safety Update volume 7 issue 11, June 2014: S1.\n"
}